Answers are grounded in this paper and cite their sources.
Objective. To evaluate the levels of sex hormones: estrone (E1), estradiol (E2), estriol (E3), progesterone (P4), testosterone (T), and free testosterone (FT), as well as their receptors: estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), androgen receptor (AR), and sex hormone-binding globulin (SHBG), in adolescents with acute lymphoblastic leukemia (ALL) before treatment initiation and after completion of the remission consolidation phase. Materials and methods. The study was conducted from 2023 to 2025 and included adolescents of both sexes with ALL (n=40). Levels of sex hormones (E1, E2, E3, P4, T, FT), their receptors (ERα, ERβ, AR), and SHBG were measured before treatment and after completion of remission consolidation using enzyme-linked immunosorbent assay (ELISA). Data from apparently healthy adolescents (n=40) were used as reference values. Statistical analysis was performed using Statistica 10 software. Results. In girls with ALL (n=20), before treatment E1 decreased 46.5-fold, E3 1.5-fold, P4 34.2-fold, T 16.0-fold, and FT 28.3-fold, while E2 and SHBG increased 3.9-fold and 2.2-fold, respectively. After consolidation phase III, E1 increased 51.8-fold, E2 decreased 3.9-fold and normalized, whereas E3, P4, T, and FT remained below normal values by 10.0-, 15.2-, 2.7-, and 4.3-fold, respectively. ERα and ERβ exceeded normal values by 1.4- and 2.2-fold, respectively, while SHBG remained elevated 2.2-fold. In boys with ALL (n=20), before treatment E1 decreased 1.7-fold, E2 3.1-fold, P4 4.3-fold, T 21.0-fold, and FT 5.6-fold, while SHBG increased 1.5-fold. After consolidation phase III, E1 exceeded normal values 1.6-fold in 50.0 % (n=10) of boys and remained 4.5-fold below normal in the remaining 50 % (n=10). E2, E3, and P4 remained below normal values by 1.6-, 2.2-, and 1.8-fold, respectively. In 50 % (n=10) of boys, T exceeded normal values 2.9-fold, whereas in the remaining 50 % (n=10) it remained 5.3-fold below normal. FT and AR remained below normal values by 2.9- and 2.0-fold, respectively. SHBG remained elevated 1.8-fold. Conclusion. The obtained data indicate the necessity for dynamic endocrinological monitoring of adolescents with ALL during chemotherapy. The identified disturbances in hormonal profile, as well as alterations in SHBG, ERα, ERβ, and AR levels, require comprehensive assessment and, when necessary, individualized correction in collaboration with a pediatric endocrinologist.
No takes yet. Share an insight, caveat, or question.
Dzhavadov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: